RALLYBIO CORPORATION (RLYB) Operating Margin
- Operating margin · 12 months: Value -4291.49%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -4291.49% | Operating income / revenue. Period ending 2026-06-30. $-27.72M ÷ $646.00K × 100 ≈ -4291.49% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -27.72M USD | Operating Income (Loss) |
| Revenue | 646.00K USD | |
| Cost of products and services | (m) | |
| Research and development | 11.43M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-27.72M | $646.00K | (m) | $11.43M | (m) | -4291.49% |
| 2026-03-31 | $-32.13M | $858.00K | (m) | $16.74M | (m) | -3744.41% |
| 2025-12-31 | $-33.06M | $858.00K | (m) | $19.60M | (m) | -3853.61% |
| 2025-09-30 | $-38.26M | $638.00K | (m) | $23.33M | (m) | -5996.87% |
| 2025-06-30 | $-43.40M | $725.00K | (m) | $27.42M | (m) | -5986.34% |
| 2025-03-31 | $-50.38M | $812.00K | (m) | $34.30M | (m) | -6204.31% |
| 2024-12-31 | $-60.50M | $600.00K | (m) | $41.51M | (m) | -10082.67% |
| 2024-09-30 | $-70.00M | (m) | (m) | $50.05M | (m) | (m) |
| 2024-06-30 | $-77.30M | (m) | (m) | $55.09M | (m) | (m) |
| 2024-03-31 | $-80.34M | (m) | (m) | $55.28M | (m) | (m) |
| 2023-12-31 | $-78.93M | (m) | (m) | $53.54M | (m) | (m) |
| 2023-09-30 | $-74.91M | (m) | (m) | $48.41M | (m) | (m) |
| 2023-06-30 | $-74.41M | (m) | (m) | $47.23M | (m) | (m) |
| 2023-03-31 | $-71.94M | (m) | (m) | $44.24M | (m) | (m) |
| 2022-12-31 | $-67.88M | (m) | (m) | $40.69M | (m) | (m) |
| 2022-09-30 | $-63.11M | (m) | (m) | $35.99M | (m) | (m) |
| 2022-06-30 | $-54.23M | (m) | (m) | $28.84M | (m) | (m) |
| 2022-03-31 | $-47.14M | (m) | (m) | $25.52M | (m) | (m) |
| 2021-12-31 | $-45.65M | (m) | (m) | $26.91M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-25.30M | (m) | (m) | $17.63M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |